ArticleFrontiers in medicine2026
Effectiveness and renal safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis patients with chronic kidney disease stages 4-5: a real-world cohort study in China.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While dupilumab is widely used for atopic dermatitis (AD), its safety and effectiveness in patients with severe renal failure remain insufficiently studied. Objective: To evaluate the real-world effectiveness and renal safety of dupilumab in this population. Methods: This cohort study included 30 adult moderate-to-severe AD patients with Chronic Kidney Disease (CKD) stages 4-5. Patients were divided into a dupilumab-treated group ( Results: The dupilumab group showed a numerically greater PP-NRS reduction at Day 30 (4.6 vs. 2.7 points) with a trend toward sustained improvement; however, the between-group difference did not reach statistical significance in the mixed-effects model ( Conclusion: Dupilumab was associated with a numerical trend toward greater improvement in pruritus compared with conventional therapy, and was not associated with statistically detectable acceleration of renal function decline in AD patients with CKD stages 4-5. These preliminary findings require confirmation in larger prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.